Inhibition of Liver Metastasis of Human Gastric Carcinoma by Angiogenesis Inhibitor TNP-470
Overview
Authors
Affiliations
The anti-tumor and anti-metastatic effects of TNP-470, an angiogenesis inhibitor, and mitomycin C (MMC), a representative anti-neoplastic agent, were investigated using our established liver-metastasizing gastric carcinoma line, AZ-H5c. AZ-H5c was injected into the spleen of nude mice which had been randomly divided into 4 groups; a control group given saline solution, a group receiving 15 mg/kg TNP-470, a group receiving 30 mg/kg TNP-470 and a group receiving 2 mg/kg MMC. TNP-470 was given s.c. on alternate days for 5 weeks from day 10 after intrasplenic injection, and MMC was administered intraperitoneally (i.p.) once a week from day 10 after intrasplenic injection. In the control group, liver metastasis developed in 13 of 16 mice (81%). Liver metastasis developed in 6 of 11 mice (55%) receiving MMC. In contrast, liver metastasis developed in 4 of 8 mice (50%) receiving 15 mg/kg TNP-470, and in 0 of 14 mice (0%) receiving 30 mg/kg TNP-470. However, TNP-470 had no effect on the tumor growth. These results indicate that the angiogenesis inhibitor TNP-470 has a strong inhibitory activity against in vivo liver metastasis of human gastric carcinoma.
Zhu B, Zhan W, Li Z, Wang Z, He Y, Peng J World J Gastroenterol. 2007; 13(8):1162-9.
PMID: 17451194 PMC: 4146988. DOI: 10.3748/wjg.v13.i8.1162.
Wang X, Tu L, Wang L, Zhou J J Zhejiang Univ Sci B. 2006; 7(10):837-43.
PMID: 16972327 PMC: 1599809. DOI: 10.1631/jzus.2006.B0837.
Poon R, Fan S, Wong J Ann Surg. 2003; 238(1):9-28.
PMID: 12832961 PMC: 1422670. DOI: 10.1097/01.sla.0000075047.47175.35.
Ishikura H, Kawarada Y, Furuya M, Kondo S, Kato H, Yoshiki T Jpn J Cancer Res. 2001; 92(1):67-73.
PMID: 11173546 PMC: 5926580. DOI: 10.1111/j.1349-7006.2001.tb01049.x.
Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K Jpn J Cancer Res. 1998; 89(9):963-9.
PMID: 9818033 PMC: 5921950. DOI: 10.1111/j.1349-7006.1998.tb00655.x.